Last reviewed · How we verify
NCT04266860
Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients
NA trial testing Experimental - Test Results and Education in Lupus Nephritis in 166 participants. Completed in 1 March 2013.
1 June 2012
Quick facts
| Lead sponsor | Qure Healthcare, LLC |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 166 |
| Start date | 1 March 2012 |
| Primary completion | 1 June 2012 |
| Estimated completion | 1 March 2013 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Experimental - Test Results and Education
Conditions studied
- Lupus Nephritis — all drugs for Lupus Nephritis →
- Lupus Erythematosus, Systemic — all drugs for Lupus Erythematosus, Systemic →
Sponsor
Qure Healthcare, LLC — full company profile →
Who can join
Eligibility, any sex, with Lupus Nephritis or Lupus Erythematosus, Systemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will collect high-quality randomized controlled data from a nationally representative sample of practicing rheumatologists to determine how they currently manage patients with SLE (systemic lupus erythematosus) and how the results of DxTerity's IFN-1 (interferon type I) test change clinical decision making.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04266860
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lupus Nephritis
Currently open trials in the same condition.
- NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
- NCT07109986 — UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis · Phase 1 · recruiting
- NCT07053891 — LUPKYNIS Drug-use Results Survey · recruiting
- NCT07015983 — A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I · Phase 2 · recruiting
- NCT06711887 — Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants · Phase 3 · recruiting
Other Qure Healthcare, LLC trials
Trials by the same sponsor.
- NCT07099001 — Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay · NA · completed
- NCT05702385 — Clinical Utility Study for Exo-PDAC · NA · withdrawn
- NCT05603299 — Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test · NA · withdrawn
- NCT05910697 — Clinical Utility of MyProstateScore 2.0 P2 · NA · terminated
- NCT05525806 — Clinical Utility Study for MyProstateScore+ · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04266860 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qure Healthcare, LLC
- Last refreshed: 16 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04266860.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing